New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts STRO-001 Targets CD74, Eradicates B-Cell Hematologic Malignancy & Prolongs Survival A Powerful Attack on Multiple Myeloma & Lymphoma SOUTH SAN FRANCISCO, July 17, 2017 – STRO-001, Sutro...
Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize? – InVivo https://invivo.pharmamedtechbi.com/IV005100/Cancers-NextGen-Smart-Bomb-Who-Will-Be-First-To-Weaponize ...
Biotechnology: Saving Lives & Transforming Healthcare in the 21st Century Modern biotechnology is a young industry. But in just a few decades, the entrepreneurs, scientists, researchers and investors working in this field have firmly established themselves at the...
Sutro Appoints Lobacki as Director; Leonard, Krishnan & Levy as Advisors SOUTH SAN FRANCISCO, April 27, 2017 –Sutro Biopharma Inc. is adding an expert in drug commercialization to its board of directors, appointing clinical and scientific advisors and promoting a...
Sutro ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival in Tumor Models SOUTH SAN FRANCISCO, April 3, 2017 – STRO-001, an antibody drug conjugate developed by Sutro Biopharma Inc., demonstrated potent anti-tumor activity in multiple...